Infusion Reactions: Severe infusion reactions occurred with the administration of ERBITUX in approximately 3% of patients, rarely with fatal outcome (<1 in 1000). Approximately 90% of severe infusion reactions were associated with the first infusion of ERBITUX. Severe infusion reactions are characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and hypotension (see WARNINGS and ADVERSE REACTIONS). Severe infusion reactions require immediate interruption of the ERBITUX infusion and permanent discontinuation from further treatment. (See WARNINGS: Infusion Reactions and DOSAGE AND ADMINISTRATION: Dose Modifications.)
ERBITUX™ (Cetuximab) is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR).
ERBITUX, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy.
ERBITUX (Cetuximab) administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.
The effectiveness of ERBITUX is based on objective response rates (see CLINICAL STUDIES). Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX.
Media Articles Related to Erbitux (Cetuximab)
Tumor location in colorectal cancer may influence survival
Source: Colorectal Cancer News From Medical News Today [2015.02.26]
The two halves of the human colon have different embryonic origins and gene expression patterns, and these differences may also play a role in cancer biology, according to a study published in the...
Keck Medicine of USC researchers trace origins of colorectal cancer tumor cells
Source: Colorectal Cancer News From Medical News Today [2015.02.12]
Big Bang' model of tumor growth provides view into how to stop cancer before it startsFor the first time, Keck Medicine of the University of Southern California (USC) cancer researchers have...
Colorectal cancer survivors who smoke 'have double risk of death'
Source: Colorectal Cancer News From Medical News Today [2015.02.04]
Study finds that colorectal cancer survivors who smoke have twice the risk of death compared to non-smoking counterparts, adding to evidence of links between smoking and cancer.
Cancer fear and discomforting thoughts impact colorectal cancer screening uptake
Source: Colorectal Cancer News From Medical News Today [2015.01.29]
Men and women who worry about cancer are more likely to want to get screened for colon cancer, but feeling uncomfortable at the thought of cancer makes them less likely to actually go for the test...
Incidence of colorectal cancer increasing in young adults
Source: Colorectal Cancer News From Medical News Today [2015.01.26]
The incidence of colorectal cancer (CRC) among young adults ages 20-39 years has increased during the past 20-30 years, despite declining rates of CRC for the U.S. population overall.
Published Studies Related to Erbitux (Cetuximab)
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. [2011.08.10]
PURPOSE: Cancer and Leukemia Group B conducted a randomized phase II trial to investigate two novel chemotherapy regimens in combination with concurrent thoracic radiation therapy (TRT)... CONCLUSION: The combination of pemetrexed, carboplatin, and TRT met the prespecified criteria for further evaluation. This regimen should be studied further in patients with locally advanced unresectable nonsquamous NSCLC.
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. [2011.07]
BACKGROUND: The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC)... CONCLUSIONS: These results confirm the efficacy of cetuximab plus FOLFOX-4 in the first-line treatment of patients with KRAS wild-type mCRC and confirm KRAS mutation status as an effective predictive biomarker. The small number of tumors with BRAF mutations precluded the drawing of definitive conclusions concerning the predictive or prognostic utility of this biomarker.
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.06.18]
BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival... INTERPRETATION: This trial has not confirmed a benefit of addition of cetuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorectal cancer. Cetuximab increases response rate, with no evidence of benefit in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional mutational analysis of their tumours. The use of cetuximab in combination with oxaliplatin and capecitabine in first-line chemotherapy in patients with widespread metastases cannot be recommended. FUNDING: Cancer Research UK, Cancer Research Wales, UK Medical Research Council, Merck KGgA. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. [2011.05.20]
PURPOSE: The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken... CONCLUSION: The addition of cetuximab to FOLFIRI as first-line therapy improves survival in patients with KRAS wild-type mCRC. BRAF tumor mutation is an indicator of poor prognosis.
Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. [2011.05]
CONCLUSION: Early evidence has shown cetuximab to be effective in the treatment of HNSCC, and it should be used to enhance, but not replace, current treatment paradigms until further phase III data are available.
Clinical Trials Related to Erbitux (Cetuximab)
Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer [Active, not recruiting]
The purpose of the study is to determine in patients with Non Small Cell Lung Cancer
refractory to previous chemotherapy whether concomitant treatment with cetuximab and
pemetrexed improves progression-free survival compared with cetuximab monotherapy.
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer [Active, not recruiting]
The purpose of this study is to determine if the addition of a unique targeted agent called
Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard
treatment with chemotherapy and radiation.
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Pancreatic Cancer [Suspended]
Eligible patients with pancreatic cancer will be treated with dual agent monoclonal antibody
consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
Study of Erbituxâ¢ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors [Completed]
The purpose of this clinical research study is to establish the maximum tolerated dose and
recommended Phase II dose of Erbitux™ in combination with Irinotecan in pediatric and
adolescent patients with refractory solid tumors.
FLOX in Combination With Cetuximab in First-Line Treatment of Colorectal Cancer [Active, not recruiting]
The main objective of this trial is to explore the effect of combining an established
chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin
(Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®) in first-line treatment of
metastatic colorectal cancer. The trial will investigate two regimens of FLOX plus cetuximab,
in which FLOX is given continuously or intermittently, compared to standard FLOX without
Reports of Suspected Erbitux (Cetuximab) Side Effects
Infusion Related Reaction (62),
Acne (48), more >>
Page last updated: 2015-02-26